Updates in the Use of Biosimilars in the Management of Retinal Eye Disorders

Carl D. Regillo, MD, and Jennifer I. Lim, MD, emphasize the high regulatory standards of equivalence and safety of biosimilars in considering the role they will play in the evolving treatment landscape for retinal disorders.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, talk about the potential cost savings as well as other real-world implications associated with the use of biosimilars in clinical practice.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, caution against the ophthalmic use of biosimilar products approved for systemic use. They also review how indications for biosimilars are granted upon approval.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, review clinical trial data for biosimilar products, with interpretation of safety data when comparing to the biologic reference products.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, discuss how evolving understanding regarding bioequivalence and the safety of biosimilars may lead to their wider use in the treatment of retinal disorders.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, share historical perspective on the safety of biosimilars and their use in medicine.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, review the regulatory oversight process regarding biosimilars after they have entered the market.

Carl D. Regillo, MD, and Jennifer I. Lim, MD, provide an overview of the development and clinical evaluation of biosimilar agents.